Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden

Fig. 4

Increased CD3−/CD56+ NK cells proliferation in peripheral blood of PV and ET patients treated with PegINFα. PBMC were collected from patients prior to and after at least 10 weeks of treatment and analyzed for surface markers CD3 and CD56 and intra-cellular marker Ki-67. a shows CD56+ frequency and b shows frequency of Ki-67+ CD56+ NK cells

Back to article page